As a founding member of the Lung Ambition Alliance, AstraZeneca is increasing screening rates and diagnostic testing, with partnerships such as the one with Qure.ai and many others. “Lung cancer ...

In the study (P46.06 – “Cell-Free DNA (cfDNA) Methylation Assay Allows for Early Detection and Identification of Lung Cancer” ), plasma samples of 37 lung cancer patients and 71 asymptomatic ...

The algorithm enables earlier detection of lung cancer using routine general practice data. The study showed discrimination, calibration, sensitivity, and specificity under various cut-off points ...

Source Reference: Buma AIG, et al "Lung cancer detection by electronic nose analysis of exhaled breath: A multicenter prospective external validation study" Ann Oncol 2025; DOI: 10.1016/j.annonc ...

About Viz.ai Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700 hospitals and health systems in the U.S. and Europe.

The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence ...

Using this algorithm, they were able to correctly classify more than 85% of the samples as coming from lung cancer patients or those with chronic pulmonary diseases.

The FDA has granted 510 (k) clearance to qCT LN Quant, an AI solution that aids clinicians in finding lung nodule diameters, malignancy risk and management approaches, according to a manufacturer ...